185 related articles for article (PubMed ID: 31049636)
1. [Molecular tumor board in uro-oncology-from a pathologist's view].
Gaisa NT; Kristiansen G; Perner S
Urologe A; 2019 Jul; 58(7):747-751. PubMed ID: 31049636
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
3. Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.
Alessandrini L; Perin T; Kadare S; Del Pup L; Memeo L; Steffan A; Colarossi L; Berretta M; De Paoli P; Canzonieri V
Curr Cancer Drug Targets; 2018; 18(5):410-420. PubMed ID: 29189158
[TBL] [Abstract][Full Text] [Related]
4. Variant classification in precision oncology.
Leichsenring J; Horak P; Kreutzfeldt S; Heining C; Christopoulos P; Volckmar AL; Neumann O; Kirchner M; Ploeger C; Budczies J; Heilig CE; Hutter B; Fröhlich M; Uhrig S; Kazdal D; Allgäuer M; Harms A; Rempel E; Lehmann U; Thomas M; Pfarr N; Azoitei N; Bonzheim I; Marienfeld R; Möller P; Werner M; Fend F; Boerries M; von Bubnoff N; Lassmann S; Longerich T; Bitzer M; Seufferlein T; Malek N; Weichert W; Schirmacher P; Penzel R; Endris V; Brors B; Klauschen F; Glimm H; Fröhling S; Stenzinger A
Int J Cancer; 2019 Dec; 145(11):2996-3010. PubMed ID: 31008532
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
6. [Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].
Kornienko K; Tahbaz R; Plage H; Schlomm T
Urologe A; 2022 Mar; 61(3):311-322. PubMed ID: 35157098
[TBL] [Abstract][Full Text] [Related]
7. [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges].
Holch JW; Westphalen CB; Hiddemann W; Heinemann V; Jung A; Metzeler KH
Dtsch Med Wochenschr; 2017 Nov; 142(22):1676-1684. PubMed ID: 29078213
[TBL] [Abstract][Full Text] [Related]
8. Pathologists and liquid biopsies: to be or not to be?
Hofman P; Popper HH
Virchows Arch; 2016 Dec; 469(6):601-609. PubMed ID: 27553354
[TBL] [Abstract][Full Text] [Related]
9. The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology.
Matias-Guiu X; Stanta G; Carneiro F; Ryska A; Hoefler G; Moch H;
Virchows Arch; 2020 Apr; 476(4):491-497. PubMed ID: 32124002
[TBL] [Abstract][Full Text] [Related]
10. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
11. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Schwaederle M; Parker BA; Schwab RB; Fanta PT; Boles SG; Daniels GA; Bazhenova LA; Subramanian R; Coutinho AC; Ojeda-Fournier H; Datnow B; Webster NJ; Lippman SM; Kurzrock R
Oncologist; 2014 Jun; 19(6):631-6. PubMed ID: 24797821
[TBL] [Abstract][Full Text] [Related]
12. [Molecular-Genetic Diagnosis and Molecular-Targeted Therapy in Cancer: Challenges in the Era of Precision Medicine].
Miyachi H
Rinsho Byori; 2015 Oct; 63(10):1188-93. PubMed ID: 26897855
[TBL] [Abstract][Full Text] [Related]
13. [Molecular tumor board prostate cancer].
Seitz AK; Heck MM; Kamer MW; Grüllich C
Urologe A; 2019 Jul; 58(7):752-759. PubMed ID: 31049637
[TBL] [Abstract][Full Text] [Related]
14. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
15. Focusing on Preinvasive Neoplasia: A Molecular Frontier at the Pathologist's Fingertips.
Borczuk AC
Arch Pathol Lab Med; 2017 Dec; 141(12):1604-1605. PubMed ID: 29189065
[No Abstract] [Full Text] [Related]
16. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
17. [The molecular tumor board].
Missios P; Beha J; Bitzer M; Malek NP
Chirurg; 2021 Nov; 92(11):1011-1015. PubMed ID: 34406439
[TBL] [Abstract][Full Text] [Related]
18. Support of a molecular tumour board by an evidence-based decision management system for precision oncology.
Lamping M; Benary M; Leyvraz S; Messerschmidt C; Blanc E; Kessler T; Schütte M; Lenze D; Jöhrens K; Burock S; Klinghammer K; Ochsenreither S; Sers C; Schäfer R; Tinhofer I; Beule D; Klauschen F; Yaspo ML; Keilholz U; Rieke DT
Eur J Cancer; 2020 Mar; 127():41-51. PubMed ID: 31982633
[TBL] [Abstract][Full Text] [Related]
19. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
[TBL] [Abstract][Full Text] [Related]
20. [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].
Bibeau F; Frugier H; Denouel A; Sabourin JC; Boissiere-Michot F
Bull Cancer; 2009 Dec; 96 Suppl():S15-22. PubMed ID: 20034866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
